Taysha gene therapies reports first quarter 2022 financial results and provides corporate update

Initiated clinical development of tsha-102 for rett syndrome under recently approved clinical trial application (cta) with preliminary phase 1/2 data expected by year-end 2022

TSHA Ratings Summary

TSHA Quant Ranking